On May 8, 2026 Ascendo Biotechnology reported that it has successfully completed an oversubscribed financing round, supported by a strong group of institutional investors, including Taiwania Capital Management Corporation (TaiAx Life Science Fund, L.P.), Yuanta Venture Capital Co., Ltd., Maxpro Investment Co., Ltd., Chenghan Investment Co., Ltd, Darly2 Venture, lnc., TECO Capital Investment Co., Ltd, Industrial Technology Investment Corporation (ITIC), Beiley Biofund Inc., Chang Hwa Bank Venture Capital Co., Ltd., and First Venture Capital Co., Ltd.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This strong investor support reflects growing confidence in our differentiated approach to targeting innate immune checkpoints, a novel strategy aimed at addressing significant unmet needs in oncology and autoimmune diseases, where current therapies remain limited in efficacy.
Ascendo Biotechnology was founded by Dr. Yen-Ta Lu, a physician from Mackay Memorial Hospital. Our core technologies originate from Taiwan-based clinical and translational research, forming the foundation of our proprietary innate immune checkpoint platform.
Proceeds from this financing will be used to advance our lead program, ASD141, through key clinical milestones in its Phase I trial and to prepare for Phase II development. In parallel, we will also advance IND-enabling studies for ASD001.
ASD141 has demonstrated encouraging early clinical signals, including immune cell activation observed at low- and mid-dose levels, with multiple patients achieving stable disease. As dose escalation continues, we aim to further validate its therapeutic potential and explore its ability to expand response rates beyond current immunotherapy limitations.
We look forward to continuing our clinical progress and advancing global collaborations and licensing discussions to accelerate the development of our pipeline.
We sincerely thank our investors and partners for their support as we move into the next phase of growth.
(Press release, Ascendo Biotechnology, MAY 8, 2026, View Source [SID1234665310])